Congress Materials - Las Vegas Dermatology 2025
2025 Las Vegas Dermatology | Sep11-13 | Las Vegas, NV
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Icotrokinra, a Novel Targeted Oral Peptide (IL-23R-inhibitor), in Adolescents With Moderate-to-Severe Plaque Psoriasis: Results of Subgroup Analyses From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (ICONIC-LEAD)
This poster will be available after Sep 11 2025
Inhibition of structural damage progression with guselkumab, a selective IL-23i, in participants with active PsA: Results through Week 24 of the phase 3b, randomized, double-blind, placebo-controlled APEX study
This poster will be available after Sep 11, 2025
Treatment of Plaque Psoriasis Involving High-Impact Sites With Icotrokinra: Subgroup Analyses of the Phase 3, ICONIC-LEAD Trial
This poster will be available after Sep 11 2025
Copies of these presentation are for personal use only and may not be reproduced without permission from ASCO® or the author of this presentation.
